Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAX014 in NMIBC
NCT03854721Phase 1Completed
- Sponsor
- Vaxiion Therapeutics
- Start
- May 2019
- Primary completion
- Mar 2023
- Modality
- Oncolytic Viruses, Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VAX014 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Vaxiion Therapeutics. Primary endpoints: Maximum Tolerated Dose up to 28 days and Treatment-Emergent Adverse Events up to 20 weeks. Started May 2019; status: completed.
02
Drugs
VAX014
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03854721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03854721.